OCTREOTIDE

PRESENTATION: 50micrograms in 1mL, 100microgram in 1mL or 500micrograms in 1mL ampoules.

INDICATION: Carcinoid Syndrome, reducing pancreatic secretions, reducing pancreatic hormone secretion and other endocrine disorders

DOSE AND ADMINISTRATION: See UKINETS bitesize guidance If unsure always consult with Endocrinology.

Subcutaneous injection

- Give undiluted.

Bolus intravenous injection

- Dilute each mL (any strength) with 1-9mL of sodium chloride 0.9%.

Continuous intravenous infusion

Concentration	Administration instructions	Administration rate
12.5micrograms/hr	300micrograms in 250mL of sodium chloride 0.9%	10mL/hr
25micrograms/hr	600micrograms in 250mL of sodium chloride 0.9%	10mL/hr
50micrograms/hr	1200micrograms in 250mL of sodium chloride 0.9%	10mL/hr

STABILITY: Physically and chemically stable for 24 hours. Note: Sun Pharmaceutical Octreotide product expiry reduces to 8 hours at 25°C.

Critical Care Guidelines: OCTREOTIDE	
Authors: Erin Fraser, Dr A Hurry	
Document Version: 1	**Authoriser:** Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: January 2024	**Review Date:** January 2026



UKINETS bitesize guidance

Critical Care Guidelines: OCTREOTIDE	
Authors: Erin Fraser, Dr A Hurry	
Document Version: 1	**Authoriser:** Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: January 2024	**Review Date:** January 2026

References

1. UKINETS Bitesize guidance on periop management of Carcinoid syndrome
2. Woltering EA, Wright AE, Stevens MA, et al. Development of effective prophylaxis against Intra-operative carcinoid crisis. Journal of Clinical Anesthesia 2016; 32: 189–193
3. Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 2016;159:358-67
4. Kinney MAO, Warner ME, Nagorny DM, et al. Perianaesthetic risks and outcomes of Abdominal Surgery for metastatic carcinoid tumours. British Journal of Anaesthesia 2001; 87(3):447-52
5. Castillo JG, Filsoufi F, Adams DH, et al. Management of patients undergoing multivalvular Surgery For carcinoid heart disease: the role of the anaesthetist. British Journal of Anaesthesia 2008; 101(5): 618-26
6. Injectable medicines guide – Octrotide (version 9). Available from Injectable Medicines Guide - Display - Octreotide - Intravenous - Version 9 - IVGuideDisplayMain.asp (medusaimg.nhs.uk) Last updated 5/9/23. Accessed 3/11/23.
7. Summary of Product Characteristics – Octreotide 100micrograms/mL (Hospira). Available from: Octreotide 100 micrograms/1ml Solution for Injection - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk) Last updated 15/06/22. Accessed 3/11/23.